Strategic partnership NanoHybrids collaborates on development and manufacture of gold nanoparticles for cancer hyperthermia with Siva Therapeutics, indicating a readiness for co-development and contract manufacturing opportunities in high-value oncology imaging and therapy applications.

Imaging leadership Specialization in silica-coated gold nanoparticles for multi-modality imaging and real-time functional biology, presenting a clear value proposition for labs and imaging centers seeking enhanced contrast and targeted molecular imaging capabilities.

Tailored solutions Conjugation services and receptor-targeted nanoparticles suggest sales potential in personalized diagnostics and therapeutics, offering adjustable surface chemistries and targeting moieties for specific patient cohorts.

Market fit signals Current revenue under one million and recent collaboration in 2017 imply a growing startup with potential for strategic deals, clinical collaborations, and early-access programs in oncology imaging markets.

Global reach potential Austin-based but with a global relevance in biomedical imaging; scalable nanoparticle platforms and integrations with existing imaging modalities position NanoHybrids for international distributors or OEM partnerships.